Zydus Lifesciences to Launch Semaglutide Variants for Global Markets

Zydus Lifesciences, a leading Indian pharmaceutical, is preparing to launch semaglutide variants, the active ingredient in antidiabetic and weight-loss drugs, as the patent nears expiration in 2026.

The firm is expected to invest over ?100 crore on a new, modern production facility to coincide with this launch.

Moreover, Zydus is working on a novel - and cheaper - method to produce semaglutide to make this more affordable for the global community for diabetes and obesity management.

Also Read: Building a Successful Pharma Brand in India: The Role of Scientific Communication

In its pursuit to make things easier for patients, Zydus is also in the process of developing a new all-in-one device that is able to deliver semaglutide in numerous strengths to address both diabetes and weight management.

Zydus is presently running clinical trials with this device in India and plans a day-one launch in the Indian market. In addition, Zydus is looking to partner with someone to expand their presence in emerging markets and increase access to this very important drug.

Zydus' announcement comes after a significant financial result in Q3, with US sales increasing 30.8% to ?2,409.6 crore thanks to demand for specialty and complex generics, while domestic sales increased 6.7% to ?1,947 crore.

 Zydus plans to leverage its manufacturing strength and its use of innovative delivery systems to address the global semaglutide market. It is hopeful it could be the low-cost and convenient treatment option for patients around the world.